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Abstract: Fine-Needle Aspiration (FNA) is the most widely used and cost-effective preoperative test for the initial 
evaluation of a thyroid nodule, although it has limited diagnostic accuracy for several types of tumors. Patients will often 
receive cytological report of indeterminate cytology and are referred to surgery for a more accurate diagnosis. An 
improved test would help physicians rapidly focus treatment on true malignancies and avoid some unnecessary treatment 
of benign tumors. This review will discuss current molecular markers that may improve thyroid nodule diagnosis. 
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INTRODUCTION 
  Thyroid nodules are commonly found in clinical practice. 
An estimated 4-7% of the adult population develop a 
clinically detectable thyroid nodule during their lifetime and 
this prevalence increases with age [1]. The advent of thyroid 
ultrasound, however, allows for an increasing number of 
nodules to be diagnosed. It is now recognized that nodules 
are detected at a subclinical level and are present in an 
estimated 67% of the general population [2,3]. The detection 
of a subclinical thyroid nodule demands a careful 
preoperative evaluation, since it may represent a thyroid 
malignancy.  
  Currently, serological tests and modern imaging 
techniques are employed for the clinical evaluation of a 
thyroid nodule. It is generally regarded that fine needle 
aspiration (FNA) cytology is the best non-surgical diagnostic 
tool for distinguishing a benign from a malignant thyroid 
nodule. Although FNA is the gold standard test for the 
preoperative assessment of a thyroid nodule, its accuracy 
varies greatly with histological subtype. Diagnosis is 
accurate for papillary thyroid carcinoma (PTC) in 
approximately 90-100% of FNA specimens. However, FNA 
accuracy is much lower for nodular hyperplasia (HN), 
follicular adenoma (FTA), Hürthle cell adenoma (HCA), 
follicular carcinoma (FTC), Hürthle cell carcinoma (HCC) 
and the follicular variant of papillary thyroid carcinoma 
(FVPTC) [4,5]. Notably, a high percentage of nodules 
classified as indeterminate were subsequently found to be 
FVPTC [6,7].  
  About 30% of all FNAs will be diagnosed as 
indeterminate. Only 10-25% of all indeterminate lesions on  
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FNA prove to be malignant, the majority of patients are 
unnecessarily subjected to resource-intensive surgery and its 
potential complications [3,8,9]. 
  To improve the diagnostic accuracy, it has been 
suggested that nodules should be stratified according risk of 
malignancy. The National Cancer Institute (NCI) recently 
sponsored a conference to review the State of Science for the 
use of FNA in the management of thyroid nodule [10]. 
Among the topics, the experts discussed the diagnostic 
terminology and morphological criteria for the cytological 
diagnosis of thyroid lesions. The committee has proposed a 
six-category scheme, according with the predicted 
probability of malignancy: (1) benign, (2) follicular lesion of 
undetermined significance (FLUS), (3) follicular neoplasm 
(e.g., suspicious for follicular or Hürthle neoplasm), (4) 
suspicious for malignancy, (5) malignant, and (6) non-
diagnostic [11-13]. According to this scheme, the 
indeterminate category encompasses three subcategories, i.e. 
2, 3 and 4.  
  Although FNA is an important technique for the triage of 
thyroid nodules and this system represents a major step 
forward to the standardization of the thyroid FNA report, 
there is still a large ‘gray zone’ in FNA-cytology. Therefore, 
it is clinically important to have molecular markers that, in 
conjunction with FNA, can identify the subset of patients 
who have a malignant nodule.  
PAX8/PPAR  REARRANGEMENTS AND RAS POINT 
MUTATIONS AS A DIAGNOSTIC TOOL  
  In 2000, Kroll et al. reported an intrachromosomal 
translocation involving chromosomal regions 2q13 and 3p25 
in human tumors arising from thyroid follicular epithelial 
cells. This recurrent translocation was reported in five FTCs 
but was not detected in any benign thyroid lesions or PTC 
[14]. The authors suggested that PAX8-PPAR  may aid in the 
differential diagnosis of FTC and benign thyroid lesions 
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  Further analysis demonstrated that this rearrangement 
was found in up to 55% of FTAs [15,16]. Additionally, the 
overall prevalence of PAX8-PPAR  rearrangement in FTC 
and its variant HCC is lower than the initially reported (for 
details, see review [17]).  
  The mechanisms by which PAX8-PPAR  may act are not 
fully understood. Interestingly, a new rearrangement in 
which a sequence of PPAR  is fused to CREB3L2 gene at 
chromosome 7q34 (CREB3L2- PPAR ) was reported in a
FTC [18]. Since  PPAR  was found associated with both 
rearrangements, it has been suggested that the disruption of 
this gene may contribute to the pathogenesis of the disease. 
Several studies demonstrated that the fusion protein 
increases cell growth, cell viability and induces anchorage 
independent growth while decreases apoptosis in vitro. There 
is no evidence, however, that this protein affect 
tumorigenesis  in vivo (for details see review [19]).
Therefore, it is still not clear whether additional events are 
needed to promote tumorigenesis.  
  Few studies have investigated whether activating 
mutation in RAS genes, previously associated with 
pathogenesis of follicular tumors [20-22], may cooperate 
with  PAX8/PPAR  rearrangement in the pathogenesis of 
FTC.  
  Based on combined analysis of mutation profiling 
(PAX8/PPAR  and RAS) with HBME1 and Galectin 3 
(LGALS3) expression, it was suggested that conventional 
FTC develop through a distinct and non-overlapping 
pathway: one involving RAS and another involving
PAX8/PPARG  rearrangement [23]. FTCs with 
PAX8/PPARG  rearrangement were found to express 
LGALS3 while FTCs with RAS mutation were found to 
express HBME1. Additionally, the authors observed 
difference in the clinical-pathological features in the two 
groups. Tumors harboring PAX8-PPAR  rearrangement tend 
to present at a younger age, be smaller in size, have a 
solid/nested growth pattern and, more frequently reveal 
vascular invasion.  
 Given  that  the  PAX8-PPAR  rearrangement was found in 
a higher proportion of FTC (30%) and in one case of FTA 
with a thick capsule and immunohistochemical profile 
characteristic of thyroid cancer, the authors suggested it may 
represent a pre-invasive (in situ) FTC in which the invasion 
was overlooked by the pathologist. In view of the fact that 
RAS mutations were found in similar proportion of FTA 
(48%) and FTC (52%), the authors also suggested that FTC 
harboring RAS mutations developed through a benign FTA 
stage and therefore, it may be precursor lesions for RAS-
positive FTC [23]. It is still not clear yet whether nodules 
with RAS mutations have malignant potential and should be 
surgically removed. Because RAS mutation was also 
associated with worse prognosis and progression to 
undifferentiated thyroid carcinoma, some groups claim that 
surgical removal of RAS-positive FTA may be justifiable to 
prevent tumor progression [24].  
 Intriguingly, PAX8-PPAR  and RAS mutations were 
rarely found in HCA and HCC, corroborating with previous 
analysis which suggested that Hürthle tumors may develop 
through a distinct pathways [23]. 
CAN SOMATIC MUTATIONS ALONG THE 
RET/RAS/RAF PATHWAY IMPROVE DIAGNOSTIC 
ACCURACY OF NODULES CLASSIFIED AS 
INDETERMINATE ON FNA?  
  Mutations of genes coding for effectors along the MAPK 
pathway (RET/PTC, RAS and BRAF) have been described 
in about 70% of PTC and are mutually exclusive [25]. 
Although diagnosis of PTC is correct in most of FNA 
specimens, several studies have investigated whether the use 
of BRAF V600E or RET/PTC could improve the accuracy of 
thyroid FNA biopsy [26-31]. Although BRAF or RET/PTC 
are highly specific for the diagnosis of PTC, they are of 
limited value in the preoperative diagnosis on those nodules 
with an indeterminate FNA cytology.  
 Recently, few studies assessed feasibility and 
significance of the use of a panel of tumor-specific mutations
in the preoperative diagnosis of a thyroid nodule. The 
studies, discussed bellow, are summarized in Table 1.
 Nikiforov  et al., reported that the combination of BRAF,
RAS, RET/PTC and PAX8/PPAR  mutations improved the 
accuracy of cytological diagnosis, particularly samples with 
indeterminate cytology. The detection of any mutation was 
highly predictive of malignancy; the specificity approached 
to 100% [24]. Although the authors declared that the test 
improved the sensitivity, in comparison with cytology alone, 
the sensitivity was lower (71%) in nodules commonly 
classified as indeterminate. Additionally, when the cytology 
samples from indeterminate were reviewed again and 
assigned to FLUS, follicular neoplasm or suspicious for 
malignancy subcategories, the sensitivity was 100%, 75% 
and 60% respectively. Worth mentioning that although RAS
and PAX8/PPAR  were highly specific for malignancy, these 
mutations have been previously found in FTA and other 
benign lesions (for details see [17]).  
 Cantara  et al., have also evaluated the diagnostic utility 
of BRAF, RAS, RET/PTC, TRK and PAX8/PPAR  mutations.
The authors found that this panel of tumor-associated 
mutations correctly identified cancer in 78.2%, while 
cytology identified 58.9% of the thyroid cancers. In the 
group of indeterminate nodules (n=41), molecular markers 
predicted cancer in 6 out of 7 samples. In the group of 
suspicious for cancer (n=54), the panel of markers predicted 
cancer in 37 samples while missed the diagnosis in 9 
samples. All predicted cancer proved to be PTC at final 
histology (Table 1). Their results demonstrated that 
molecular analysis on FNA samples is feasible and that, 
when including the analysis of a complete panel of 
oncogenes, increase the diagnostic accuracy of conventional 
cytology [32]. 
 Mose  et al., sought to determine the clinical utility of 
testing BRAF, RAS RET/PTC and TRK mutations in thyroid 
FNA biopsy [33]. Molecular testing for a panel of mutations 
in thyroid FNA biopsies with indeterminate cytology 
revealed a sensitivity of 27%, specificity of 95%, PPV of 
66% and NPV of 78%. Their results pointed out that this 
panel of markers missed the diagnosis of cancer in 21 out of 
29 samples; all proved to be FTC, HCC and FVPTC at final 
histology. When considered FNA biopsies that were 
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Table 1.  Diagnosis of Nodules Classified as Indeterminate on FNA Using a Panel of Mutations
Studies Samples Markers 
Sensitivity 
(%)
Specificity
(%)
PPV NPV  Histology
A False-
Negative 
False-
Positive 
[24]  n=52 
BRAF
V600E 
NRAS (61) 
HRAS (61) 
KRAS (12, 
13) RET/PTC
1 RET/PTC 3
PAX8/PPAR 
71
(100,75, 
60)
B
100
(100, 
100,100)
B
100
(100,100,100)
B
83
(100,79,50)
B
17 PTC, 4
FTC, 4 
FTA and 
27 HN 
6/21 (4 
PTC and 2
FTC)  
0
[32]  n=41
C
BRAF
V600E 
NRAS (12, 
13, 61) 
HRAS (12, 
13, 61) 
KRAS (12, 
13, 61) 
RET/PTC 1 
RET/PTC 3 
TRK
PAX8/PPAR 
87 97  85  97 
7 PTC, 26
FTA and 
8 HN 
1/7 (PTC) 1 FTA 
[32]  n=54
D
BRAF
V600E 
NRAS (12, 
13, 61) 
HRAS (12, 
13, 61) 
KRAS (12, 
13, 61) 
RET/PTC 1 
RET/PTC 3 
TRK
PAX8/PPAR 
80 100 100  47 
46 PTC, 4
FTA and 
4 HN 
9/46 
(PTC) 
0
[33]  n=110 
BRAF
V600E 
NRAS (12, 
13, 61) 
KRAS (12, 
13, 61) 
RET/PTC 1 
RET/PTC 3 
NTRK1 
27
(12)
E
95
(98)
E
66
(38)
E
78
(65)
E
29 FTA, 6
HCA, 40 
HN, 6 LT,
19
FVPTC, 8
FTC and 2
HCC
21 (4 
FTC, 2 
HCC, 15 
FVPTC) 
4 FTA 
[34]  n=117 
BRAF
V600E 
NRAS (61) 
HRAS (61) 
KRAS (12, 
13) RET/PTC
1 RET/PTC 3
PAX8/PPAR 
63 100 100  93 
79 non-
neoplastic,
18 FTA 
and 20 
PTC, 
8 PTC  0 
APTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; FTA, follicular thyroid adenoma; HN, hyperplasia; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma; 
FVPTC, follicular variant of PTC; LT, lymphocytic thyroiditis.  
BWhen indeterminate nodules were assigned to the propose NCI categories (FLUS, follicular neoplasm or suspicious for malignancy) the sensitivity was 100%, 75% and 60%, 
respectively. The PPV and NPV are given according to NCI categories. 
CNodules classified as indeterminate. 
DNodules classified as suspicious for malignancy. 
EResults including nodules classified as indeterminate (n=110) and suspicious for malignancy (n=27). All false-positive were due to RAS mutation.592 Current Genomics, 2011, Vol. 12, No. 8 Janete M. Cerutti
(n= 27), sensitivity of 12%, specificity of 98%, PPV of 38% 
and NPV of 65% (Table 1).  
 Ohori  et al., investigated the BRAF, RAS, RET/PTC and 
PAX8/PPAR  mutational status of nodules classified as 
FLUS. The main focus was to determine whether molecular 
markers could help to better refine FLUS category (with an 
estimated probability of malignancy between 5 and 10%). 
Although the molecular test had a high specificity, the 
sensitivity was quite low (60%). Molecular markers were 
negative in seven out of 19 cases of PTC. The authors 
suggested that, although not all PTC were detected by the 
panel of common molecular markers, a positive molecular 
test helped to refine the FLUS case into high-risk and low-
risk categories [34].  
  A caveat concerning the use of this panel of tumor-
associated markers is that BRAF mutation is most commonly 
associated with classical variant of PTC [35,36] and a high 
percentage of nodules classified into indeterminate category 
are FVPTC. Moreover, it has been reported that mutations in 
the tissue samples were not found in cytological material 
from same patient [32]. It is still unclear whether the false 
negative results was due to the fact that the FNA biopsy was 
not representative of the tumor cells or there has been a 
contamination with DNA or RNA isolated from non-
malignant, stromal, inflammatory or blood cells. Finally, 
searching for RET/PTC rearrangement was possible in about 
50% of samples due to low quantity of material or bad 
quality of RNA [32]. Therefore, not only proper collection of 
samples is a mandatory step but also a reasonably amount of 
starting material is needed to isolate both DNA and RNA.  
  While this diagnostic approach may have lower 
sensitivity for indeterminate nodules, the preoperative 
detection of these mutations, particularly for BRAF, may 
help to identify patients at high risk of recurrence and death 
[35-39]. Beyond the impact in patient management it will 
probably have an impact in therapeutics [40-42].  
MOLECULAR CLASSIFICATION USING 
EXPRESSION PROFILING  
  A number of candidate biomarkers have been identified 
last years. Among the candidate markers that are thought to 
discriminate the benign from the malignant thyroid 
carcinoma is LGALS3 (Galectin-3). LGALS3 was initially 
described as a potential marker that could discriminate 
benign from well differentiated thyroid carcinomas with high 
sensitivity and specificity [43,44]. Although some studies 
confirmed the initial findings, others have found LGALS3 
expression in normal thyroid and benign lesions. 
Additionally, a high percentage of FTC, HCC and FVPTC 
are negative for LGALS3. It has been suggested that the 
reasons for this discrepancy might be related to the 
difference in technical procedures and antibody clone used 
[7] (for details see [17]).  
  Taking into consideration the technical problems, a 
prospective multicenter study was conducted to test the 
utility of LGALS3 for testing nodules classified as 
indeterminate on FNA-cytology [7]. Although LGALS3 had 
a specificity of 93%, the overall sensitivity of the test was 
78%. Although the authors declared that 71% of unnecessary 
thyroid surgical procedures could be avoided, 29 cancers 
(22%) would be missed. Considering the implications of 
false-negative findings, the use of LGALS3 alone in clinical 
practice should be interpreted cautiously.  
  Other groups have explored whether LGALS3, in 
combination with other markers, could improve the 
diagnostic accuracy of FNA. It has been suggested a panel 
that includes LGALS3, FN1 and/or HBME1 [45]. Although 
the combination of these markers detects most carcinomas, 
false-positive results have been reported [46-48].  
  Comparative genome-wide transcriptional profiling has 
been widely used for identifying molecular markers. Using 
microarray analysis, Barden et al., described a 105-gene 
expression classifier that differentiated between the FTA 
from FTC with high accuracy [49].  
  Based on the combination of PCSK2, CCDN2 and PLAB
expression, the authors developed a new model that predict 
the diagnosis of FTC and FTA with high sensitivity (100%) 
and specificity (96.7%) [50].  
 TFF3  has been described as the most promising marker 
for diagnosis of FTC. The authors found that TFF3
expression is markedly decreased in malignant thyroid 
carcinomas [51]. Further analysis demonstrated that TFF3 
was highly expressed in normal thyroid compared to thyroid 
tumors, although no difference was reported among FTA, 
FTC, PTC and FVPTC by immunohistochemistry [52]. It has 
been suggested that the expression of TFF3, along with other 
molecular markers, may improve diagnosis of thyroid nodule 
[53,54]. 
AN ANTIBODY-BASED TEST FOR THE DIAGNOSIS 
OF THYROID NODULE FNAS CLASSIFIED AS 
INDETERMINATE  
  We previously performed gene expression profiling of 
FTC, FTA and normal thyroid (http://cgap.nci.nih.gov/ 
SAGE) [55]. This profiling and subsequent validation using 
quantitative PCR (qPCR) revealed that four genes (DDIT3, 
ITM1, ARG2, C1orf24) differed between FTA and FTC, and 
a linear combination of expression levels distinguish the 
benign from malignant with a predictive accuracy of 83% 
[56]. The four candidate markers were over-expressed in 
FTC and, therefore, carcinoma markers. The two 
commercially available antibodies (ARG2 and DDIT3) were 
validated in an independent set of FTA and FTC paraffin-
embedded samples (n=59). We achieved a specificity of 
90.6% and sensitivity of 85.2%. We next produced and 
tested antibodies for ITM1 and C1orf24 in the thyroid 
samples previously tested for DDIT3 and ARG2. In addition, 
we also tested all carcinoma markers on a wider range of 
benign and malignant lesions (n=127; FTA, HN, FTC, 
FVPTC and PTC). By adding C1orf24 and ITM1, we 
achieved a specificity of 90% and sensitivity of 100% [57]. 
However, the two best markers for detecting malignancy 
(C1orf24 and ITM1), had the drawback of few false-
positives cases. All false-positive were benign lesions with 
Hürthle components.  
  To improve the accuracy of our test, we next performed 
two SAGE libraries; one for the false-positive HCA and one 
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next validated by qPCR (n=76; FTA, HCA, FTC, CCH and 
FVPTC). To validate the results obtained from qPCR 
analysis and to define the final panel that would yield best 
diagnostic accuracy, the two best HCA markers (PVALB 
and KLK1) were tested, in combination with carcinoma 
markers (DDIT3, ITM1, ARG2 and C1orf24), in an 
independent set of 82 thyroid paraffin-embedded sections. 
We identified PVALB as a new marker that can be used in 
combination with C1orf24 and ITM1 for a more accurate 
diagnosis of thyroid nodules. By adding PVALB we 
achieved a specificity of 97% and maintained sensitivity for 
detection of carcinoma.  
  Importantly, this antibody-based test was not only more 
accurate than mRNA based test but also these antibodies can 
effectively be used in FNA specimens [57,58].  
  Other groups have also investigated the expression of 
DDIT3, ITM1 and C1orf24 in thyroid tumors. C1orf24 
expression was found in malignant thyroid tumors and in 
benign lesions scattered cells with Hürthle metaplasia [59].  
  A multigene marker panel that includes EMMPRIN, 
Autotaxin, DDIT3, LGALS3 and TFF3 was tested in FTC, 
FVPTC and FTA [60]. The authors reported a sensitivity of 
90% for DDIT3, although they found a specificity of 21%. 
Given that our false-positive cases were HCA, one possible 
explanation for the decrease in specificity is that adenomas 
tested may have Hürthle cell components. This sample set 
also showed very low sensitivity (65% and 40%) and 
specificity (62% and 51%) for LGALS3 and TFF3, 
correspondingly.
  Recently, a combination of TFF3, STT3A ( ITM1)a n d  
C1orf24 was tested in FNA biopsy [61]. In these set of 
samples, the expression of TFF3 did not differ between 
benign and malignant. Although ITM1 was differentially 
expressed between FTA and malignant tumors, it was 
detected in benign lesions. Similarly, the authors found 
C1orf24 expression in few benign lesions. Whether the 
benign lesions tested have Hürthle cell components, it is not 
clear. However, we and others have previously reported that 
ITM1 and C1orf24 give false-positive results in HCA and 
benign lesions with Hürthle cells [56-59,62]. Additionally, 
the authors have investigated ITM1 and C1orf24 at mRNA 
levels and the expression of these markers performed in 
paraffin-embedded sections showed to be more robust than 
quantitative PCR performed in snap-frozen samples or FNA 
samples.  
  All together, these findings suggests that a panel of 
markers that are able to distinguish all thyroid lesions may 
represent a helpful adjunct to the FNA cytology in order to 
rule in malignancy as a probable diagnosis, thus guiding the 
selection of patients who might benefit from thyroidectomy. 
Our findings suggest that o antibody-based test provide 
greatest cost effective potential for improving the diagnosis 
from FNA samples, further analysis testing these markers in 
a greater number of FNA specimens will clarify whether it 
can effectively help the preoperative evaluation of nodules 
classified as indeterminate and, therefore, be incorporated in 
most laboratories for the routine evaluation of thyroid 
nodules.  
FUTURE PERSPECTIVES IN DIAGNOSIS OF 
THYROID NODULES  
  The PI3K pathway has been implicated in the 
pathogenesis of thyroid tumors [21,63-66]. Liu et al.
indentified genetic alterations in genes along the PI3K/AKT 
pathways in FTC and undifferentiated thyroid carcinoma 
(UTC). Mutations and copy number gain were commonly 
found in UTC, although they were much less common in 
FTC. Copy gains of PIK3CB (45%) and mutation in RAS
(20%) were the most common genetic alteration found in 
FTC. Although PIK3CB copy number gain was identify in a 
number of malignant lesions, this genetic variation should be 
further investigated in FTA samples [21]. 
  We recently identified 6-non synonymous changes in 
IDH1 gene in a panel of 164 thyroid samples [67]. The non 
synonymous mutations identified in our study were not 
identified in matched thyroid normal samples, suggesting 
that they were somatically acquired. Remarkably, IDH1
mutations were highly prevalent in FTC, HCC and in 
FVPTC, while were not identified in the benign FTA and its 
variant [67]. Although these data indicate that IDH1 
mutation analysis might help the diagnosis of indeterminate 
thyroid nodules, further analysis is still needed to determine 
the role of IDH1 in the pathogenesis of thyroid tumors and if
its mutations preferentially accumulate in specific tumor 
subtypes. Interestingly, others have also indentified IDH1 
variants in FTC and UTC [68].  
  In addition to the specific biomarkers found through gene 
expression profiling or mutational analysis, several 
published reports have also suggested the role of 
microRNAs (miRNAs) in the diagnosis of thyroid tumors. In 
fact, the genome-wide miRNA expression profile revealed 
that miR-197 and miR-346 are over-expressed in FTC 
compared to FTA [69]. Additionally miR-221 and miR-222 
have been found to be consistently over-expressed in PTC 
[70-74]. It is still not clear whether the measurement of the 
miRNAs levels is a suitable tool for the preoperative 
diagnosis of thyroid nodules classified as indeterminate by 
FNA. However, some authors believe that miRNA will add 
significantly to the diagnosis of thyroid nodules [75]. One 
potential problem one might face is the small RNA fraction 
obtained from FNA biopsy, and, therefore, whether this 
approach is technologically feasible or not. Additionally, the 
difference observed in miRNA expression may not be 
sufficient to distinguish a benign from a malignant thyroid 
nodule.  
THE NEXT STEPS  
  Currently, several studies have evaluated the diagnostic 
potential of candidate tumor markers (alone or in 
combination). Although very promising classifiers have been 
described, a common criticism is that the results are often 
contradictory, even for the most commonly used markers or 
for the panel of tumor-associated mutation.  
  From the technical standpoint, one can predict that will 
happen for all markers discussed here. One possible 
explanation is that studies use diverse protocols, very few 
markers have been validated in multiple studies, the analyses 
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  Before the development of a preoperative diagnostic test 
that can be used in routine, we need to take into account 
several issues. Markers are usually validated on frozen 
sections or paraffin-embedded samples. FNA specimen may 
have contaminations with non-tumor cells. Therefore, assays 
based on quantitative level of expression (mRNA or protein) 
and mutation-based diagnostic test should take into account 
both tumor heterogeneity and contamination, all of which 
may reduce the sensitivity and specificity. Moreover, assays 
based on RNA are a challenge for routine clinical pathology, 
not only because RNA is much more susceptible to 
degradation than DNA but also because mRNA yields from 
FNA samples are variable and may not provide enough 
material for multigene analysis. Assays, which are observer-
dependent, should be avoided. Therefore, a minimal number 
of genes are required and qualitative (positive or negative) 
results is desirable.  
  Finally, a next important step for candidate molecular 
markers for thyroid tumors is the clinical testing of FNA 
samples in large multi-institutional trials.  
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